Prescriber Update Vol. 36 No. 1 www.medsafe.govt.nz March 2015 ISSN[removed]print)

First Page		Document Content
Date: 2015-03-04 19:33:56 Selective serotonin reuptake inhibitors Amines Organochlorides Organofluorides Piperazines Atomoxetine Adverse effect Bupropion Bevacizumab Chemistry Organic chemistry Medicine		Prescriber Update Vol. 36 No. 1 www.medsafe.govt.nz March 2015 ISSN[removed]print) Add to Reading List Source URL: www.medsafe.govt.nz Download Document from Source Website File Size: 952,21 KB Share Document on Facebook

	United States Government Accountability Office GAO Report to the Ranking Member, Committee on Finance, U.S. Senate DocID: 1riEa - View Document
	Lettre d’information du réseau GCO - Spéciale ASCOLes Groupes Coopérateurs en Oncologie à l’ASCO 2016 Les Groupes Coopérateurs en Oncologie (GCO) seront représentés au 52ème congrès de l’ASCO (Ameri DocID: 1qX2r - View Document
	References [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC DocID: 1qSc2 - View Document
	CURRICULUM VITAE Mary W. Redman, Ph.D. Current Address: DocID: 1qCPH - View Document
	CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for DocID: 1pDeC - View Document